AbbVie Inc. vs TotalEnergies SE: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and TotalEnergies SE across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating TotalEnergies SE, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and TotalEnergies SE is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $182.3B for TotalEnergies SE, while their respective market capitalizations stand at $451.5B and $165.0B. AbbVie Inc. is headquartered in United States and TotalEnergies SE operates from France, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

TotalEnergies SE: TotalEnergies reported $182.344 billion in 2025 revenues from sales and $13.127 billion in net income attributable to TotalEnergies. The company remains a multi-energy major: oil and gas production, LNG, refining, marketing, electricity, and renewables all sit inside one capital-allocation system led by CEO Patrick Pouyanne.

AbbVie Inc. and TotalEnergies SE pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and TotalEnergies SE.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

TotalEnergies SE business model: TotalEnergies makes money from an integrated energy chain: exploration and production, LNG, refining and chemicals, marketing and services, electricity generation, power trading, renewable assets, and customer energy services.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of TotalEnergies SE.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

TotalEnergies SE competitive advantage: TotalEnergies has an integrated LNG platform, upstream assets across multiple basins, downstream and marketing positions, and a growing power portfolio. Its advantage is breadth across molecules, refined products, and electrons.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and TotalEnergies SE each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

TotalEnergies SE growth strategy: TotalEnergies' strategy centers on low-cost oil and gas production, LNG integration, disciplined downstream operations, renewable power capacity, electricity customers, and cash returns to shareholders.

A closer look at the financial trajectory of AbbVie Inc. and TotalEnergies SE rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

TotalEnergies SE: TotalEnergies reported $182.344 billion in 2025 revenues from sales, down from $195.610 billion in 2024 as hydrocarbon prices declined. Net income attributable to TotalEnergies was $13.127 billion, while adjusted net income was $15.587 billion and adjusted EBITDA was $40.555 billion.